NASDAQ: LTRN
Lantern Pharma Inc Stock Forecast, Predictions & Price Target

Be the first to know when Wall Street analysts revise their LTRN stock forecasts and price targets.

Forecast return on equity

Is LTRN forecast to generate an efficient return?

Company
N/A
Industry
93.13%
Market
-61.61%

Forecast return on assets

Is LTRN forecast to generate an efficient return on assets?

Company
N/A
Industry
35.76%

LTRN earnings per share forecast

What is LTRN's earnings per share in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
-$1.81
Avg 2 year Forecast
-$1.14
Avg 3 year Forecast
-$1.62

LTRN vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
LTRN$4.32N/AN/A
ATNM$1.46$4.00+173.97%Buy
CALC$3.25$16.00+392.31%Buy
IPSC$0.56$6.00+977.20%Strong Buy
SKYE$1.45$15.00+934.48%Buy

Lantern Pharma Stock Forecast FAQ

What is LTRN's earnings growth forecast for 2025-2027?

(NASDAQ: LTRN) Lantern Pharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 4.11%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 16%.

Lantern Pharma's earnings in 2025 is -$19,248,695.On average, 1 Wall Street analyst forecast LTRN's earnings for 2025 to be -$19,546,945, with the lowest LTRN earnings forecast at -$19,546,945, and the highest LTRN earnings forecast at -$19,546,945. On average, 1 Wall Street analyst forecast LTRN's earnings for 2026 to be -$12,311,335, with the lowest LTRN earnings forecast at -$12,311,335, and the highest LTRN earnings forecast at -$12,311,335.

In 2027, LTRN is forecast to generate -$17,495,056 in earnings, with the lowest earnings forecast at -$17,495,056 and the highest earnings forecast at -$17,495,056.

If you're new to stock investing, here's how to buy Lantern Pharma stock.

What is LTRN's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: LTRN) forecast ROE is N/A, which is considered weak.

What is LTRN's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: LTRN) Lantern Pharma's current Earnings Per Share (EPS) is -$1.78. On average, analysts forecast that LTRN's EPS will be -$1.81 for 2025, with the lowest EPS forecast at -$1.81, and the highest EPS forecast at -$1.81. On average, analysts forecast that LTRN's EPS will be -$1.14 for 2026, with the lowest EPS forecast at -$1.14, and the highest EPS forecast at -$1.14. In 2027, LTRN's EPS is forecast to hit -$1.62 (min: -$1.62, max: -$1.62).

What is LTRN's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: LTRN) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 35.76%.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.